Loss of daptomycin susceptibility in clinical Staphylococcus epidermidis infection coincided with variants in WalK

Daptomycin (DAP) is key in treating multidrug-resistant Staphylococcus infections. Diminished susceptibility to DAP is emerging among Staphylococcus epidermidis strains although mechanisms for non-susceptibility (NS) remain poorly understood. We report a case of persistent S. epidermidis bacteremia...

Descripción completa

Detalles Bibliográficos
Autores principales: Brazeau, Nicholas F, Levinson, Kara J, Schranz, Asher, Moser, Kara A, Hollis, Ian, Iyer, Prashanth, Chien, Christopher, Bowen, Amanda, van Duin, David, Lachiewicz, Anne, Andermann, Tessa, Jones, Melissa, Miller, Melissa, Juliano, Jonathan J, Bartelt, Luther A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Case Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658547/
https://www.ncbi.nlm.nih.gov/pubmed/33214904
http://dx.doi.org/10.1093/emph/eoaa031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658547/
https://www.ncbi.nlm.nih.gov/pubmed/33214904
http://dx.doi.org/10.1093/emph/eoaa031

Ejemplares similares